20:40 , May 18, 2018 |  BioCentury  |  Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
02:28 , May 18, 2018 |  BC Week In Review  |  Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
23:06 , May 14, 2018 |  BC Extra  |  Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
19:51 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

HATs off to epigenetics

Although the epigenetics field is heating up, most compounds on the market and in development are clustered around the same small set of targets. Now, a team led by AbbVie Inc. (NYSE:ABBV) has uncovered an...
23:53 , Aug 23, 2017 |  BC Extra  |  Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein ( CREBBP ; CBP) as an epigenetic strategy for treating prostate cancer is mounting. In a paper published in...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Cellcentric, ZoBio deal

CellCentric and ZoBio partnered to develop compounds against epigenetic drug targets for primarily oncology indications along with other therapeutic areas. ZoBio will use its Target Immobilized NMR Screening technology to screen its fragment library against...
00:21 , Jun 21, 2012 |  BC Extra  |  Company News

CellCentric, ZoBio in epigenetic deal

CellCentric Ltd. (Cambridge, U.K.) and ZoBio B.V. (Leiden, the Netherlands) partnered to develop compounds against epigenetic drug targets. ZoBio will use its Target Immobilized NMR Screening technology to screen its fragment library against targets chosen...
08:00 , Jan 23, 2012 |  BioCentury  |  Strategy

Epigenetics land grab

After about 20 years of academic research on epigenetics, large drug developers have decided the time is right to move in, making bets on biotechs that can provide platforms and compounds. Last week, Genentech Inc....
08:00 , Mar 1, 2010 |  BC Week In Review  |  Company News

Cellcentric, Takeda deal

CellCentric granted Takeda exclusive rights to develop and commercialize an undisclosed epigenetic program. The program is in development to treat cancer. CellCentric is eligible for over $200 million in upfront, milestone and royalty payments. Takeda...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Tripartite motif-containing 24 (TRIM24) In vitro, mouse and Drosophila studies suggest that inhibiting TRIM24 could help restore p53 tumor suppressor function to treat cancer....